{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-019877","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2023-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.062143+00:00","generated_at":"2026-06-13T08:41:58.939043+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Atossa Therapeutics regains Nasdaq compliance with minimum bid price requirement","bullets":["Received Nasdaq notice on July 13, 2023 that it regained compliance with Listing Rule 5550(a)(2).","Previously notified of deficiency on Oct 5, 2022; granted 180-day extension on April 4, 2023.","Met requirement by maintaining closing bid price >= $1.00 for 10 consecutive trading days through July 12, 2023.","Common stock (ATOS) will continue trading on Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-019877","json":"https://secwatch.observer/filing/0001437749-23-019877.json","markdown":"https://secwatch.observer/filing/0001437749-23-019877.md","text":"https://secwatch.observer/filing/0001437749-23-019877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923019877/0001437749-23-019877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923019877/atos20230713c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:41:58.939043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77caa324c17280e9fbae26bfe97ef2ac2f7fc80e","claim":"ATOSSA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"July 13, 2023, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously disclosed, on October 5, 2022, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company was init","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923019877/0001437749-23-019877-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"compliance regained"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}